International Circulation: Is there other message or important things you think we could take from this trial from your analysis of the data?

    《国际循环》：您认为从这项试验的数据分析中，我们还能得到哪些重要信息？

    Prof. Neaton：The other interesting finding that was mentioned in the presentation this morning and dealt with in more detail in our paper， which was published today in Lancet， is an understanding of the risk factors for developing some of the toxicities. As Dr. Konstam mentioned， for renal toxicities and hypotension， there was a greater risk in the high dose group over the low dose group. This however did not translate into big difference at all in terms of treatment discontinuations. We’ve initiated a series of analyses trying to identify patient characteristics that are more likely to experience these toxicities. Later this will be a very important guide for clinicians. For example， in the paper we identified that older age individuals， those who had hypercholemia as a reason for intolerance to the ACE inhibitor were more likely to develop hypercholemia on the ARB and that is an important bit of information to know.  We plan to pursue that further but there is already information in the paper regarding that issue.

    Neaton教授：我在今天早上的演讲中已经提及其他有意义的发现，论文中讲述得更加详细，也发表在《Lancet》杂志上，即对发生某种药物毒性的危险因素的理解。正如Konstam博士所说的，如肾脏毒性和低血压，高剂量组较低剂量组有较高的（此类疾病的）风险。然而这并不意味着有足够大的差异，因此不需要中断治疗。我们进行了一系列分析试图发现容易发生这种毒性反应的患者特征。这将对临床非常重要。论文中我们指出，年龄较高和高胆固醇血症患者对ACE抑制剂不耐受，更易发展为高胆固醇血症。这是需要重视的。我们计划在将来继续做进一步研究。